Maurizio Amichetti

Dr. Maurizio Amichetti


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2012 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MMMariangela La Macchia
Mariangela La Macchia
FFFrancesco Fellin
Francesco Fellin
MAMaurizio Amichetti
Maurizio Amichetti
MCMarco Cianchetti
Marco Cianchetti
SGStefano Gianolini
Stefano Gianolini
LWLamberto Widesott
Lamberto Widesott
Purpose: To validate, in the context of adaptive radiotherapy, three commercial software solutions for atlas-based segmentation. Methods and materials: Fifteen patients, five for each group, with cancer of the Head&Neck, pleura, and prostate were enrolled in the study. In addition to the treatment planning CT (pCT) images, one replanning CT (rCT) image set was acquired for each patient during the RT course. Three experienced physicians outlined on the pCT and rCT all the volumes of interest (VOIs). We used three software solutions (VelocityAI 2.6.2 (V), MIM 5.1.1 (M) by MIMVista and ABAS 2.0 (A) by CMS-Elekta) to generate the automatic contouring on the repeated CT. All the VOIs obtained with automatic contouring (AC) were successively corrected manually. We recorded the time needed for: 1) ex novo ROIs definition on rCT; 2) generation of AC by the three software solutions; 3) manual correction of AC. To compare the quality of the volumes obtained automatically by the software and manually corrected with those drawn from scratch on rCT, we used the following indexes: overlap coefficient (DICE), sensitivity, inclusiveness index, difference in volume, and displacement differences on three axes (x, y, z) from the isocenter. Results: The time saved by the three software solutions for all the sites, compared to the manual contouring from scratch, is statistically significant and similar for all the three software solutions. The time saved for each site are as follows: about an hour for Head&Neck, about 40 minutes for prostate, and about 20 minutes for mesothelioma. The best DICE similarity coefficient index was obtained with the manual correction for: A (contours for prostate), A and M (contours for H&N), and M (contours for mesothelioma). Conclusions: From a clinical point of view, the automated contouring workflow was shown to be significantly shorter than the manual contouring process, even though manual correction of the VOIs is always needed.

25 March 2009 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
MAMaurizio Amichetti
Maurizio Amichetti
MCMarco Cianchetti
Marco Cianchetti
DADante Amelio
Dante Amelio
RERiccardo Maurizi Enrici
Riccardo Maurizi Enrici
Giuseppe MinnitiGiuseppe Minniti
Giuseppe Minniti

14 December 2012 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
MAMaurizio Amichetti
Maurizio Amichetti
DADante Amelio
Dante Amelio
Giuseppe MinnitiGiuseppe Minniti
Giuseppe Minniti
Stereotactic radiosurgery (SRS) is an important treatment option for intracranial lesions. Many studies have shown the effectiveness of photon-SRS for the treatment of skull base (SB) tumours; however, limited data are available for proton-SRS.

7 March 2012 in Cancers
Verified
Journal Article
Open access
PDF file
DADante Amelio
Dante Amelio
MAMaurizio Amichetti
Maurizio Amichetti
Despite the therapeutic advances in neuro-oncology, most patients with glioblastoma ultimately experience local progression/relapse. Re-irradiation has been poorly viewed in the past, mainly due to the overestimated risk of side effects using conventional radiotherapy. To date, thanks to the improvement of several delivery techniques, together with improved imaging capabilities, re-irradiation is a viable salvage treatment option to manage such clinical scenario. A literature overview on the feasibility and efficacy of the different irradiation modalities for recurrent glioblastoma along with considerations on areas of improvement are provided.

28 October 2011 in Cancers
Verified
Journal Article
Open access
PDF file
MAMaurizio Amichetti
Maurizio Amichetti
DADante Amelio
Dante Amelio
Despite the use of more effective multimodal treatments in high-grade glioma (HGG), the outcome of patients affected by this disease is still dismal and recurrence is a very common event. Many therapeutic approaches, alone or combined (surgery, drugs, targeted agents, immunotherapy, radiotherapy, supportive therapy), are available in the clinical armamentarium so far. The attitude of physicians is increasingly interventionist, but recurrent HGG still remains a very difficult scenario to be treated. Radiotherapy with different re-irradiation techniques is increasingly proposed as a therapeutic option with interesting results, even though the resulting duration of response is usually quite short. Most lesions re-recur locally, with inadequate identification and targeting of viable tumor being the most important cause of failure. Prognosis is affected by many patient-, tumor-, and treatment-associated prognostic factors. Radiotherapy is delivered with many advanced modalities: 3D-CRT, intensity-modulated radiation therapy, stereotactic fractionated radiotherapy, radiosurgery, and brachitherapy with or without chemotherapy administration. In order to evaluate the feasibility and efficacy of re-irradiation in this setting, we reviewed the PubMed and MEDLINE databases restricting the search to original reports published from January 1990 to June 2011. The search resulted in a total of 155 reports: 78 of them covering 2,688 patients treated with different irradiation modalities overall fulfilled the entry criteria. Radiation therapy demonstrated to be an acceptable option in recurrent HGG with good response rates and acceptable toxicity.

24 July 2013 in Thoracic Cancer
Verified
Journal Article
Closed access
PDF file
MAMaurizio Amichetti
Maurizio Amichetti
SLStefano Lorentini
Stefano Lorentini
STSandro Tonoli
Sandro Tonoli
SMStefano Magrini
Stefano Magrini